» Articles » PMID: 33127205

Podocarpusflavone A Inhibits Cell Growth of Skin Cutaneous Melanoma by Suppressing STAT3 Signaling

Overview
Journal J Dermatol Sci
Publisher Elsevier
Specialty Dermatology
Date 2020 Oct 31
PMID 33127205
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: JAK2/STAT3 pathway is involved in the development and progression of melanoma once DNA damage is caused by environment and genetic factors.

Objective: Here, we aimed to identify novel inhibitor of JAK2/STAT3 pathway and reveal the underlying mechanisms.

Methods: Eighty MedChemExpress compounds were screened by using STAT3-Luc reporter in A375 cells. Podocarpusflavone A (PCFA) was identified as an inhibitor of STAT3, which was further verified in four melanoma cell lines. The anti-melanoma effects and mechanism of PCFA were examined and explored in melanoma cells and mouse xenograft models by using Western blot and cell-counting kit-8 assay.

Results: PCFA exhibited potent inhibitory effects on melanoma both in vitro and in vivo. PCFA inhibited the activation of STAT3 through suppressing the phosphorylation of JAK2, and then restrained cell cycle and induced apoptosis of melanoma cells.

Conclusion: PCFA inhibits melanoma growth via the inhibition of JAK2/STAT3 pathway, which provides a promising therapeutic strategies of melanoma treatment.

Citing Articles

Exploring the Antimycobacterial Potential of Podocarpusflavone A from : In Vitro and In Vivo Insights.

Araujo M, Munoz Sanchez S, Simao T, Nowik N, Antunes S, Correa Pinto S Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770402 PMC: 11676425. DOI: 10.3390/ph17121560.


Podocarpusflavone alleviated renal fibrosis in obstructive nephropathy by inhibiting Fyn/Stat3 signaling pathway.

Zhu B, Han R, Ni Y, Guo H, Liu X, Li J J Nat Med. 2023; 77(3):464-475.

PMID: 36884159 DOI: 10.1007/s11418-023-01685-y.


Current understanding of epigenetics role in melanoma treatment and resistance.

Karami Fath M, Azargoonjahromi A, Soofi A, Almasi F, Hosseinzadeh S, Khalili S Cancer Cell Int. 2022; 22(1):313.

PMID: 36224606 PMC: 9555085. DOI: 10.1186/s12935-022-02738-0.